trial

FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis

NCTId NCT00486798
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Terminated
Enrollment —
Sponsored by AstraZeneca
Primary completion 2007-08
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Terminated
Enrollment
—
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2007-05
Primary completion
2007-08
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
QuetiapineRating ScalesSelf Assessment FormBlood and urine samplesSleeping pattern

Sponsors

AstraZenecaLead Sponsor

Investigators

2
Jaan Ruusa, MD,PhDPrincipal Investigator
Birgit Ekholm, MDStudy Director

Sites

13 total
Borås, SwedenDanderyd, SwedenFalköping, SwedenGothenburg, SwedenKarlskrona, SwedenMalmö, SwedenÖjebyn, SwedenPiteå, SwedenSimrishamn, SwedenStockholm, SwedenTrollhättan, SwedenVaxjo, Sweden

Linked catalysts

1
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients Wit — primary completion2007-08

Facts & assertions

3 sourced
Phase
PHASE3
Primary Completion Date
2007-08
Status
TERMINATED
relationships
The graph out of here
drug
Quetiapine
drug
Rating Scales
drug
Self Assessment Form
drug
Blood and urine samples
drug
Sleeping pattern
drug
lead_sponsor
AstraZeneca
company
indication
Bipolar Disorder
indication
Psychotic Disorders
indication
Psychotic Disorders
indication
investigator
Jaan Ruusa, MD,PhD
person
Birgit Ekholm, MD
person